Tags

Type your tag names separated by a space and hit enter

De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
Clin Transplant. 1994 Aug; 8(4):388-95.CT

Abstract

We compared the incidence of de novo tumors developing in 1165 primary adult renal allograft recipients treated with azathioprine (AZA)-prednisone (Pred)-antilymphocyte globulin (ALG) (CONV group) with that in 722 patients receiving cyclosporine (CSA) as part of double (CSA-Pred), triple (CSA-Pred-AZA), or quadruple-therapy (CSA-Pred-AZA-ALG) protocols. Mean +/- SD follow-up was 9.5 +/- 6.4 years for the CONV group and 6.2 +/- 2.7 years for the CSA group. Overall, 124 patients (10.6%) in the CONV group and 34 patients (4.7%) in the CSA group developed malignancies, with nonmelanoma skin cancers and lymphomas comprising 55% and 13% of cancers in the CONV group and 65% and 3% of cancers in the CSA group, respectively. There were no significant differences in overall cancer (p = 0.41) or skin cancer (p = 0.97) incidence between non-CSA-treated and CSA-treated patients by Kaplan-Meier life-table analysis; however, CONV-treated patients demonstrated a higher incidence of lymphoma (p = 0.05). The mean (+/- SD) time to overall and skin cancer occurrence was significantly shorter in the CSA group: 37 +/- 22 versus 90 +/- 52 months (p < 0.001) and 40 +/- 24 versus 92 +/- 52 months, respectively. When the Cox Proportional Hazard Model was utilized to assess the relative importance of age, diabetic status, donor source, sex, and immunosuppressive regimen in determining cancer development, age > or = 50 years and nondiabetic status were significant independent prognostic indicators, while immunosuppressive regimen was not. Graft and patient survival were significantly greater in CONV-treated patients developing cancer than in those who did not.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Department of Surgery, University of Minnesota, Minneapolis.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

7949545

Citation

Gruber, S A., et al. "De Novo Cancer in Cyclosporine-treated and Non-cyclosporine-treated Adult Primary Renal Allograft Recipients." Clinical Transplantation, vol. 8, no. 4, 1994, pp. 388-95.
Gruber SA, Gillingham K, Sothern RB, et al. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transplant. 1994;8(4):388-95.
Gruber, S. A., Gillingham, K., Sothern, R. B., Stephanian, E., Matas, A. J., & Dunn, D. L. (1994). De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clinical Transplantation, 8(4), 388-95.
Gruber SA, et al. De Novo Cancer in Cyclosporine-treated and Non-cyclosporine-treated Adult Primary Renal Allograft Recipients. Clin Transplant. 1994;8(4):388-95. PubMed PMID: 7949545.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. AU - Gruber,S A, AU - Gillingham,K, AU - Sothern,R B, AU - Stephanian,E, AU - Matas,A J, AU - Dunn,D L, PY - 1994/8/1/pubmed PY - 1994/8/1/medline PY - 1994/8/1/entrez SP - 388 EP - 95 JF - Clinical transplantation JO - Clin Transplant VL - 8 IS - 4 N2 - We compared the incidence of de novo tumors developing in 1165 primary adult renal allograft recipients treated with azathioprine (AZA)-prednisone (Pred)-antilymphocyte globulin (ALG) (CONV group) with that in 722 patients receiving cyclosporine (CSA) as part of double (CSA-Pred), triple (CSA-Pred-AZA), or quadruple-therapy (CSA-Pred-AZA-ALG) protocols. Mean +/- SD follow-up was 9.5 +/- 6.4 years for the CONV group and 6.2 +/- 2.7 years for the CSA group. Overall, 124 patients (10.6%) in the CONV group and 34 patients (4.7%) in the CSA group developed malignancies, with nonmelanoma skin cancers and lymphomas comprising 55% and 13% of cancers in the CONV group and 65% and 3% of cancers in the CSA group, respectively. There were no significant differences in overall cancer (p = 0.41) or skin cancer (p = 0.97) incidence between non-CSA-treated and CSA-treated patients by Kaplan-Meier life-table analysis; however, CONV-treated patients demonstrated a higher incidence of lymphoma (p = 0.05). The mean (+/- SD) time to overall and skin cancer occurrence was significantly shorter in the CSA group: 37 +/- 22 versus 90 +/- 52 months (p < 0.001) and 40 +/- 24 versus 92 +/- 52 months, respectively. When the Cox Proportional Hazard Model was utilized to assess the relative importance of age, diabetic status, donor source, sex, and immunosuppressive regimen in determining cancer development, age > or = 50 years and nondiabetic status were significant independent prognostic indicators, while immunosuppressive regimen was not. Graft and patient survival were significantly greater in CONV-treated patients developing cancer than in those who did not.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0902-0063 UR - https://www.unboundmedicine.com/medline/citation/7949545/De_novo_cancer_in_cyclosporine_treated_and_non_cyclosporine_treated_adult_primary_renal_allograft_recipients_ L2 - http://www.diseaseinfosearch.org/result/3993 DB - PRIME DP - Unbound Medicine ER -